IRMD
IRadimed Corporation
IRMD's fundamentals are strong: it turned 29% of its revenue into free cash flow and free cash flow grew 77%. At 46x earnings, it's trading above its usual 41x. Analysts expect strong earnings growth.
IRMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
IRMD's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
IRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 32x | $59.44 | -30% |
| Forward | 36x | $85.23 | — |
| Fair | 41x | $76.32 | -10% |
| Current | 46x | $85.23 | — |
| Expensive | 71x | $133 | +57% |
Historical ranges are pointers, not guarantees.
IRMD's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 36x next year's earnings, in its cheap range.
IRMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IRMD, with profitability improving.
IRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +28% |
| Q3 2026 | $1.87 | +13% |
| Q2 2026 | $1.79 | +10% |
| Q1 2026 | $1.83 | +18% |
| Q4 2025 | $1.75 | +17% |
| Q3 2025 | $1.65 | +14% |
| Q2 2025 | $1.62 | +12% |
| Q1 2025 | $1.55 | +11% |
| Q4 2024 | $1.50 | +11% |
IRMD's earnings per share have climbed steadily: $1.87 over the past year, up 13% from the year before, and higher year over year for 21 quarters in a row.
IRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2M | +14% |
| Q2 2026 | $20.5M | +0.3% |
| Q1 2026 | $22M | +13% |
| Q4 2025 | $22.7M | +17% |
| Q3 2025 | $21.2M | +16% |
| Q2 2025 | $20.4M | +14% |
| Q1 2025 | $19.5M | +11% |
| Q4 2024 | $19.4M | +11% |
IRMD's revenue has grown year over year for 23 quarters in a row: $24M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +1.4 points |
| Q2 2026 | 31% | -2 points |
| Q1 2026 | 33% | +5.1 points |
| Q4 2025 | 31% | +1.4 points |
| Q3 2025 | 32% | +0.6 points |
| Q2 2025 | 33% | +1.9 points |
| Q1 2025 | 28% | +0.9 points |
| Q4 2024 | 30% | +0.3 points |
IRMD's operating margin was 34% last quarter, up 1.4 points from the same quarter a year ago, near the top of its range since 2019.
IRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +17% |
| Q2 2026 | $5.8M | +13% |
| Q1 2026 | $7.9M | +1226% |
| Q4 2025 | $5.6M | +76% |
| Q3 2025 | $5.8M | +10% |
| Q2 2025 | $5.1M | -7.2% |
| Q1 2025 | $594.6K | -84% |
| Q4 2024 | $3.2M | -5.4% |
IRMD generated $26M in free cash flow over the past year, up 77% from the year before.
IRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +4K shares |
| 1 year | +0.1% | +15.9K shares |
| 3 years | +1.1% | +140K shares |
| 5 years | +2.2% | +272K shares |
| Available history | +4.9% | +600K shares |
IRMD has 13M diluted shares, about the same as a year ago.
IRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.2x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
IRMD has more cash than debt.
IRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 36.0 | Neutral |
IRMD's weekly RSI is 47 (neutral) and its Stochastic is 36 (neutral).
IRMD PE vs Healthcare Sector
| Metric | IRMD | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 76% above |
| PE % | 60 | 29 | 31 pts above |
IRMD is trading at 46x earnings, a 76% premium to the Healthcare sector's median of 26x.
IRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.1 | 0.1% above |
| 20 week MA | $88.2 | 3.3% below |
| 50 week MA | $92.6 | 8% below |
| 100 week MA | $77.7 | 9.7% above |
| 200 week MA | $61.2 | 39% above |
IRMD's trend is mixed: it's above three of its five weekly moving averages, and 39% above its 200-week average.
IRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.6 | $23.3 | -5.3% |
| 2021 | $23.3 | $45.9 | +97% |
| 2022 | $45.9 | $28.0 | -39% |
| 2023 | $28.0 | $47.5 | +70% |
| 2024 | $47.5 | $54.7 | +15% |
| 2025 | $54.7 | $97.5 | +78% |
| 2026 YTD | $97.5 | $85.2 | -13% |
IRMD has finished higher in four of the last six years, three of them by more than 50%. It's down 13% so far in 2026.